Spero Therapeutics (MEX:SPRO) 6-Month Price Index: N/A (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SPRO Spero Therapeutics Inc MEX:SPRO
40 GF Score
Price MXN20.74
GF Value MXN13.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Spero Therapeutics 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-22), Spero Therapeutics's 6-Month Price Index is N/A.

Spero Therapeutics  (MEX:SPRO) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Spero Therapeutics 6-Month Price Index Related Terms

MEX:SPRO vs : 6-Month Price Index Comparison

For the Biotechnology subindustry, Spero Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MEX:SPRO
40GF Score
Spero Therapeutics Inc MEX:SPRO
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics  (MEX:SPRO) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Spero Therapeutics (MEX:SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of MXN20.74 is trading 53.2% above its estimated GF Value™ of MXN13.54. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for MEX:SPRO:

  • 6-Month Price Index: N/A
  • GF Value™: MXN13.54 vs. price of MXN20.74 (53.2% above fair value)
  • GF Score™: 40/100 with 2 warning signs

No single metric tells the full story. See the MEX:SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Comparable Companies
Other Exchanges SPRO:USA2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
40GF Score

Get the complete analysis for MEX:SPRO

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN20.74
Price
MXN13.54
GF Value